Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.

ABSTRACT:

Objectives

To estimate the costs of providing extended-release injectable naltrexone (XR-NTX) and buprenorphine-naloxone (BUP-NX) following inpatient detoxification using data derived from a multisite randomized controlled trial at 8 US community-based treatment programs.

Study design

Cost data were collected for 3 intervention phases: program start-up, inpatient detoxification, and up to 24 weeks of medication induction and management visits (post detoxification). Cost analyses were from the healthcare sector perspective (2015 US$); patient costs are also reported.

Methods

We conducted site visits, administered a cost survey to treatment programs, and analyzed study data on medication and services utilization. Nationally representative sources were used to estimate u

SUBMITTER: McCollister KE 

PROVIDER: S-EPMC6345513 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature